Aegis Capital

In a report published Monday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Galectin Therapeutics (NASDAQ: GALT), and raised the price target from $7.00 to $10.00. In the report, Aegis Capital noted, “We are raising our price target on Galectin Therapeutics to reflect updated...

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju upgraded Sinovac Biotech (NASDAQ: SVA) from Hold to Buy, and named a $7.00 price target. In the report, Aegis Capital noted, “Yesterday, Sinovac reported 2Q 2013 financial results. Total revenue was reported at $17.5mm,...

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju, Ph.D. MBA reiterated a Buy rating and $4.00 price target on Neuralstem (NYSE: CUR). In the report, Aegis Capital noted, “Last week, Neuralstem reported financial results for the second quarter of 2013. The firm closed the...

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Catalyst Pharmaceutical (NASDAQ: CPRX), and raised the price target from $2.50 to $3.00. In the report, Aegis Capital noted, “Earlier this week, Catalyst reported financial results for 2Q 2013....

In a report published Thursday, Aegis Capital analyst Raghuram Selvaraju upgraded Sinovac Biotech (NASDAQ: SVA) from Hold to Buy, and named a $7.00 price target. In the report, Aegis Capital noted, “Yesterday, Sinovac reported 2Q 2013 financial results. Total revenue was reported at $17.5mm,...

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Hold to Buy, and named a $70.00 price target. In the report, Aegis Capital noted, “Earlier this week, Cubist announced that it would be buying two other antibiotics...

In a report published Monday, Aegis Capital analyst Raghuram Selvaraju initiated coverage on Neostem (NYSE: NBS) with a Buy rating and $2.50 price target. In the report, Aegis Capital noted, “We are initiating coverage of Neostem, Inc., an emerging biotechnology firm focusing on the development...

In a report published on Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and a price target of $35 on Amarin (NASDAQ: AMRN). In the report, Aegis Capital stated, "This morning, Amarin reported positive data from a Phase 1 clinical trial assessing the pharmacokinetic...

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Stemline Therapeutics (NASDAQ: STML), and raised the price target from $35.00 to $40.00. In the report, Aegis Capital noted, “Given the recent progress at Stemline Therapeutics and the fact that...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on CytRx (NASDAQ: CYTR), but lowered the price target from $8.00 to $7.00. In the report, Aegis Capital noted, “We are providing an update on the clinical programs at CytRx Corp. Earlier this month...

In a report published Monday, Aegis Capital analyst Raghuram Selvaraju maintained the rating of Buy, and lowered the price target on Pernix Therapeutics (NASDAQ: PTX) to $8.50. In the report, Aegis Capital stated, "...we are updating our projections to reflect reduced company guidance for 2013...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $80.00 price target on Valeant Pharmaceuticals International (NYSE: VRX). In the report, Selvaraju noted, “Once more, Valeant has lived up to its reputation as perhaps the most acquisitive company...

In a report published by Aegis Capital, analyst Raghuram Selvaraju initiated coverage on Stemline Therapeutics (NASDAQ: STML) with a Buy Rating and 18-Month $35 price target. Aegis Capital reported that, “In our view, Stemline Therapeutics represents a unique investment opportunity in the small-...

Aegis Capital analyst Raghuram Selvaraju published a report on Sinovac Biotech (NASDAQ: SVA) that maintained its Hold rating and raised the price target to $4 per share. Aegis Capital reported that, “Sinovac Biotech announced preliminary top-line data from the Phase 3 trial assessing the efficacy...

Aegis Capital analyst Raghuram Selvaraju published a report on China Biological Products (NASDAQ: CBPO) that maintained its Buy rating and raised the 15-Month price target from $22 to $28 per share. Aegis Capital reported that, “Compared to the previous quarters of 2012, 4Q 2012 revenue saw a dip...